| abstract |
REFERS TO COMPOUNDS DERIVED FROM PYRIMIDINE AND PYRIDINE OF FORMULA (I) WHERE X1 IS CH O N; R1 IS C (= O) NHR6, PHENYL, PYRROLYL, AMONG OTHERS, WHERE R6 IS H, ALKYL (C1-C6), HALOALKYL (C1-C6), AMONG OTHERS; R2 IS H O (C1-C6) ALKYL; R3 AND R4 ARE EACH H, HALOGEN, AMINO, ALKYL (C1-C6), AMONG OTHERS; R5 IS PHENYL, PYRIDINYL, BENZO [b] THIOFEN-2-ILO, THIOPHENYL, AMONG OTHERS; A IS -NHC (= O) -, C (= O) NH-, NHC (= O) NH, AMONG OTHERS. PREFERRED COMPOUNDS ARE: 4- (1-HYDROXY-1-METHYL-ETHYL) -N- {2-METHYL-3- [1-METHYL-5- (3-METHYL-UREIDE) -6-OXO-1,6- DIHYDRO-PYRIDIN-3-IL] -PHENYL} -BENZAMIDE, 6-DIMETHYLAMINE-N- {2-METHYL-3- [1-METHYL-5- (3-METHYL-UREIDE) -6-OXO-1,6- DIHYDRO-PYRIDIN-3-IL] -PHENYL} -NICOTINAMIDE, AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. SAID COMPOUNDS ARE INHIBITORS OF BRUTON'S TYROSINE KINASE (Btk) BEING USEFUL IN THE TREATMENT OF RHEUMATOID ARTHRITIS, PSORIASIS, CROHN'S DISEASE, ASTHMA |